Doctor of Optometry Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Sherrol Reynolds

Optometrist Davie, FL Doctor of Optometry

NPI 1639244437 CMS profile 495436

3200 S University Dr, Nsu The Eye Institute Suite 1402, Davie, FL 33328

Open in the dashboard

General payments

$59,669

103 records reported · program years 2019–2025

Research payments

$1,200

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Sherrol Reynolds of Davie, FL is reported in the CMS Open Payments database as having received $59,669 across 103 general payments and $1,200 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Optometrist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $6,128 21
2024 General $4,205 15
2023 General $270 3
2022 General $26,792 24
2021 General $5,174 13
2021 Research $1,200 1
2020 General $1,053 4
2019 General $16,047 23

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sherrol Reynolds
  • Optometrist median
  • Middle half of Optometrist
  • National median

In program year 2025, general payments to Sherrol Reynolds were reported at $6,128. Among 35,373 Optometrist profiles paid that year, the median was $204 and the middle half received between $87 and $464.

Show as a table
Year Sherrol Reynolds Optometrist median Middle half National median
2019 $16,047 $159 $67–$371 $163
2020 $1,053 $72 $29–$165 $114
2021 $5,174 $125 $46–$292 $132
2022 $26,792 $162 $66–$374 $149
2023 $270 $177 $72–$406 $160
2024 $4,205 $188 $77–$427 $164
2025 $6,128 $204 $87–$464 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. LKC Technologies, Inc. $18,975 1 payment
  2. Bausch & Lomb, a division of Bausch Health US, LLC $10,082 3 payments
  3. Regeneron Pharmaceuticals, Inc. $6,832 12 payments
  4. Allergan Inc. $6,708 18 payments
  5. Carl Zeiss Meditec, Inc. $5,205 9 payments
  6. AbbVie, Inc. $4,620 10 payments
  7. Genentech USA, Inc. $3,770 6 payments
  8. CooperVision Inc. $1,266 2 payments
  9. Astellas Pharma US Inc $273 4 payments
  10. Glaukos Corporation $259 3 payments
  11. Other $1,678 35 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Education $18,975 1 payment
  2. Consulting Fee $14,080 18 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $12,625 7 payments
  4. Grant $5,000 1 payment
  5. Food and Beverage $4,144 67 payments
  6. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $3,000 1 payment
  7. Travel and Lodging $1,817 7 payments
  8. Debt forgiveness $28 1 payment
Products named General payments · program years 2019–2025
  1. RETeval Complete $18,975 1 payment
  2. VUITY $8,638 15 payments
  3. EYLEA $5,804 12 payments
  4. CIRRUS HD-OCT $5,070 7 payments
  5. CLARUS 500 Fundus Camera $5,070 7 payments
  6. CRYSTALENS $5,000 1 payment
  7. BIOTRUE $5,000 1 payment
  8. Humphrey HFA $4,597 4 payments
  9. FORUM $4,597 4 payments
  10. Xolair $3,770 6 payments
  11. Other $5,285 66 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. F. Hoffmann-La Roche AG $1,200 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

85

Median for Optometry: 120

Drug cost

$6,501

Median for Optometry: $8,864

Branded share of claims

20%

Median for Optometry: 24.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Lumigan Bimatoprost Brand 17 $4,678
Brimonidine Tartrate Generic 25 $1,549
Latanoprost Generic 43 $274

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 27,653 Part D prescribers listed as Optometry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 12 billing codes

Paid by Medicare

$2,240

Medicare's payments for the services billed

Medicare patients

32

Average age 74

Services billed

83

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 47%
Arthritis 41%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 9 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Xolair
  • Genentech USA, Inc. $3,770
$3,770 — —
Izervay
  • Astellas Pharma US Inc $95
  • Astellas Pharma Global Development $74
$169 — —
LUMIGAN
  • AbbVie, Inc. $28
$28 17 —
XDEMVY
  • Tarsus Pharmaceuticals, Inc. $21
$21 — —
IHEEZO
  • Harrow Eye, LLC $3
$3 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 9 in the dashboard with a free account

Records

104 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Optometrist in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record